These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23258250)

  • 21. Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta-blockers.
    Varian KD; Ji X; Grodin JL; Verbrugge FH; Milinovich A; Kattan MW; Tang WHW
    ESC Heart Fail; 2020 Oct; 7(5):3049-3058. PubMed ID: 32757485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure.
    Kataoka M; Satoh T; Yoshikawa T; Nakamura I; Kohno T; Yoshizawa A; Anzai T; Ogawa S
    Circ J; 2008 Mar; 72(3):358-63. PubMed ID: 18296829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of treatment with carvedilol vs metoprolol succinate and mortality in patients with heart failure.
    Pasternak B; Svanström H; Melbye M; Hviid A
    JAMA Intern Med; 2014 Oct; 174(10):1597-604. PubMed ID: 25173681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction.
    Ibrahim NE; Gaggin HK; Turchin A; Patel HK; Song Y; Trebnick A; Doros G; Maya JF; Cannon CP; Januzzi JL
    Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):3-11. PubMed ID: 29490032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A histamine H₂ receptor blocker ameliorates development of heart failure in dogs independently of β-adrenergic receptor blockade.
    Takahama H; Asanuma H; Sanada S; Fujita M; Sasaki H; Wakeno M; Kim J; Asakura M; Takashima S; Minamino T; Komamura K; Sugimachi M; Kitakaze M
    Basic Res Cardiol; 2010 Nov; 105(6):787-94. PubMed ID: 20852875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anemia Is Associated With Blunted Response to β-Blocker Therapy Using Carvedilol　- Insights From Japanese Chronic Heart Failure (J-CHF) Study.
    Nagatomo Y; Yoshikawa T; Okamoto H; Kitabatake A; Hori M;
    Circ J; 2018 Feb; 82(3):691-698. PubMed ID: 28883225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Doughty RN; Whalley GA; Gamble G; MacMahon S; Sharpe N
    J Am Coll Cardiol; 1997 Apr; 29(5):1060-6. PubMed ID: 9120160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcome of carvedilol therapy in Japanese patients with nonischemic heart failure.
    Nagara K; Suzuki A; Shiga T; Hagiwara N
    Heart Vessels; 2020 Jul; 35(7):957-966. PubMed ID: 31970509
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of carvedilol on ventriculo-arterial coupling in patients with heart failure.
    Razzolini R; Tarantini G; Boffa GM; Orlando S; Iliceto S
    Ital Heart J; 2004 Jul; 5(7):517-22. PubMed ID: 15487269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
    Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
    Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial.
    Zebrack JS; Munger M; Macgregor J; Lombardi WL; Stoddard GP; Gilbert EM
    Pharmacotherapy; 2009 Aug; 29(8):883-90. PubMed ID: 19637941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial.
    Contini M; Apostolo A; Cattadori G; Paolillo S; Iorio A; Bertella E; Salvioni E; Alimento M; Farina S; Palermo P; Loguercio M; Mantegazza V; Karsten M; Sciomer S; Magrì D; Fiorentini C; Agostoni P
    Int J Cardiol; 2013 Oct; 168(3):2134-40. PubMed ID: 23506636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
    Otterstad JE; Ford I
    Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Uptitration of renin-angiotensin system blocker and beta-blocker therapy in patients hospitalized for heart failure with reduced versus preserved left ventricular ejection fractions.
    Verbrugge FH; Duchenne J; Bertrand PB; Dupont M; Tang WH; Mullens W
    Am J Cardiol; 2013 Dec; 112(12):1913-20. PubMed ID: 24286620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure.
    Ito H; Nagatomo Y; Kohno T; Anzai T; Meguro T; Ogawa S; Yoshikawa T
    Circ J; 2010 Aug; 74(8):1578-83. PubMed ID: 20562496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
    Mortara A; La Rovere MT; Pinna GD; Maestri R; Capomolla S; Cobelli F
    J Am Coll Cardiol; 2000 Nov; 36(5):1612-8. PubMed ID: 11079666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol.
    Metra M; Nodari S; D'Aloia A; Muneretto C; Robertson AD; Bristow MR; Dei Cas L
    J Am Coll Cardiol; 2002 Oct; 40(7):1248-58. PubMed ID: 12383572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure.
    Castro P; Vukasovic JL; Chiong M; Díaz-Araya G; Alcaino H; Copaja M; Valenzuela R; Greig D; Pérez O; Corbalan R; Lavandero S
    Eur J Heart Fail; 2005 Oct; 7(6):1033-9. PubMed ID: 16227141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial.
    Metra M; Torp-Pedersen C; Swedberg K; Cleland JG; Di Lenarda A; Komajda M; Remme WJ; Lutiger B; Scherhag A; Lukas MA; Charlesworth A; Poole-Wilson PA
    Eur Heart J; 2005 Nov; 26(21):2259-68. PubMed ID: 16040619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.